PROSPECTS OF THE USE OF DOXYCYCLINE FOR THE ANTIBIOTIC RESISTANCE
DOI:
https://doi.org/10.32782/health-2024.2.19Keywords:
doxycycline hyclate, antibiotics, antibiotic resistance, COVID-19, SARS-CoV-2.Abstract
Antibiotic resistance, i.e. the resistance of bacteria to certain antibiotics, has became an extremely important problem nowadays. Because the consequences of an irresponsible attitude to taking antimicrobial drugs can be unpredictable and extremely complex. At the same time, the development of new drugs is a time-consuming and expensive process, therefore one of the ways to solve this problem is the use of already studied antibiotics with preserved activity, which have shown their effectiveness and do not have widespread resistance, one of the representatives of which is doxycycline. Currently, according to the Standard of Medical Care “Rational Use of Antibacterial and Antifungal Drugs for Therapeutic and Prophylactic Purposes”, doxycycline is recommended for the treatment of patients with uncomplicated lower urinary tract infection caused by MRSA; with infectious diseases of bones and/or joints; in respiratory tract disease (including ENT organs) caused by MRSA with a mild or moderate degree of severity, although numerous scientific studies have demonstrated the promise of this drug in the treatment of new bacterial diseases, as well as in the combined treatment of COVID-19. Studies have shown that the combination of doxycycline with colchicine or ivermectin is especially effective in the treatment of this disease. Analysis of the assortment of doxycycline-based drugs showed that on the pharmaceutical market of Ukraine, such drugs are represented in only two dosage forms, tablets and capsules, and in only one dosage, 100 mg. At the same time, for example, in Great Britain, doxycycline tablets and capsules are registered in dosages: 20 mg, 40 mg, 50 mg, 100 mg. In addition, the presence of doxycycline in other medicinal forms, such as parenteral, suspensions for internal use, syrups on the pharmaceutical markets of other countries, was found out. Therefore, it is important to develop and manufacture in Ukraine drugs based on doxycycline with a different dosage and dosage form (aerosols, gel-emulsions, transdermal patches, etc.), since this drug is a broad-spectrum drug that does not yet have widespread resistance.
References
Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet. 2022. Vol. 399. P. 629–655. DOI: https://doi.org/10.1016/S0140-6736(21)02724-0.
Langford B.J., Soucy J.R., Leung V., So M., Kwan A.T.H., Portnoff J.S., Bertagnolio S., Raybardhan S., Mac Fadden D.R., Daneman N. Antibiotic resistance associated with the COVID-19 pandemic: a systematic review and metaanalysis. Clin Microbiol Infect. 2023. V. 29 (3). P. 302–309. DOI: 10.1016/j.cmi.2022.12.006.
Langford B.J., So M., Raybardhan S., Leung V., Westwood D., Mac Fadden D.R., Soucy J.R., Daneman N. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect. 2020. V. 26 (12). P. 1622–1629. DOI: 10.1016/j.cmi.2020.07.016.
Langford B.J., So M., Leung V., Raybardhan S., Lo J., Kan T., Leung F., Westwood D., Daneman N., Mac Fadden D.R., Soucy J.R. Predictors and microbiology of respiratory and bloodstream bacterial infection in patients with COVID-19: living rapid review update and meta-regression. Clin Microbiol Infect. 2022. V. 28 (4). Р. 491–501. DOI: 10.1016/j.cmi.2021.11.008.
Langford B.J., So M., Raybardhan S., Leung V., Soucy J.R., Westwood D., Daneman N., Mac Fadden D.R. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. Clin Microbiol Infect. 2021. V. 27 (4). P. 520–531. DOI: 10.1016/j.cmi.2020.12.018.
Кірсанов Д. Вплив пандемії COVID-19 на фармринок. Аптека.ua : вебсайт. 2021. URL: https://www.apteka.ua/article/615423.
Holmes N.E., Charles P.G.P. Safety and Efficacy Review of Doxycycline. Clinical Medicine Therapeutics. 2009. V. 1. P. 471–482. DOI: 10.4137/CMT.S2035.
Brouillard J.E., Terriff C.M., Tofen A., Garrison M.W. Antibiotic selection and resistance issues with fluoroquinolones and doxycycline against bioterrorism agents. Pharmacotherapy. 2006. V. 26 (1). P. 3–14. DOI: https://doi.org/10.1592/phco.2006.26.1.3.
Про затвердження Стандарту медичної допомоги «Раціональне застосування антибактеріальних і антифунгальних препаратів з лікувальною та профілактичною метою» : наказ МОЗ України від 23.08.2023 № 1513. URL: https://moz.gov.ua/article/ministry-mandates/nakaz-moz-ukraini-vid-23082023--1513-pro-zatverdzhennja-standartumedichnoi-dopomogi-racionalne-zastosuvannja-antibakterialnih-i-antifungalnih-preparativ-z-likuvalnoju-taprofilaktichnoju-metoju.
Gendrot M., Andreani J., Jardot P., Hutter S., Delandre O., Boxberger M., Mosnier J., Le Bideau M., Duflot I., Fonta . et al. In Vitro Antiviral Activity of Doxycycline against SARS-CoV-2. Molecules. 2020. V. 25. P. 5064. DOI: 10.3390/molecules25215064.
Yates P.A., Newman S.A., Oshry L.J., Glassman R.H., Leone A.M., Reichel E. Doxycycline treatment of high-risk COVID-19-positive patients with comorbid pulmonary disease. Therapeutic Advances in Respiratory Disease. 2020. V. 14. DOI: 10.1177/1753466620951053.
Al-Kuraishy H.M., Al-Gareeb A.I., Qusty N., Cruz-Martins N., El-Saber Batiha G. Sequential doxycycline and colchicine combination therapy in Covid-19: The salutary effects. Pulm Pharmacol Ther. 2021. V. 67. P. 102008. DOI: 10.1016/j.pupt.2021.102008.
Mahmud R., Rahman Md.M., Alam I. et al. Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial. Journal of International Medical Research. 2021. V. 49 (5). DOI: 10.1177/03000605211013550.
Alam M.T., Murshed R., Bhiuyan E., Saber S., Alam R.F., Robin R.C. A case series of 100 COVID-19 positive patients treated with combination of ivermectin and doxycycline. J. Bangladesh Coll. Phys. Surg. 2020. V. 38. P. 10–15. DOI: https://doi.org/10.3329/jbcps.v38i0.47512.
Malek A.E., Granwehr B.P., Kontoyiannis D.P. Doxycycline as a potential partner of COVID-19 therapies. ID Cases. 2020. V. 21. P. e00864. DOI: 10.1016/j.idcr.2020.e00864.
Narendrakumar L., Joseph I., Thomas S. Potential effectiveness and adverse implications of repurposing doxycycline in COVID-19 treatment. Expert Rev Anti Infect Ther. 2021. V. 19 (8). P. 1001–1008. DOI: 10.1080/14787210.2021.1865803.
Інформаційно-пошукова система «Державного реєстру лікарських засобів України». URL: http://www.drlz.com.ua/ibp/ddsite.nsf/all/index?opendocument.
The electronic medicines compendium (emc). URL: https://www.medicines.org.uk/emc/search?q=doxycycline.
Салій О. О., Саченко Є. В., Пальчевська Т. А., Страшний В. В. Сучасні шляхи доставки доксицикліну та перспективи застосування у фармації. Фармацевтична технологія. 2022. Т. 77, № 4. С. 50–61. DOI: 10.32352/0367-3057.4.22.06.
Saliy O., Popova M., Tarasenko H., Getalo O. Development strategy of novel drug formulations for the delivery of doxycycline in the treatment of wounds of various etiologies. Eur J Pharm Sci. 2024 V. 195. 106636 DOI: 10.1016/j.
ejps.2023.106636.
